PD-1 Peptide Inhibitors
AssigneeLeidos, Inc.
InventorsGabriel M. Gutierrez, Vinayaka Kotraiah, James Pannucci, Ramses Ayala
Life of this patent
Estimating the term…
Abstract
This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating sepsis; and promoting hair re-pigmentation or lightening of pigmented skin lesions.
Claims18
A method of inhibiting the progression of a hyperproliferative disorder, treating an infectious disease, enhancing a response to vaccination, treating sepsis, promoting hair re-pigmentation, or promoting lightening of a pigmented skin lesion, comprising administering to an individual in need thereof an effective amount of at least one peptide selected from the group consisting of (i) a peptide comprising the amino acid sequence SEQ ID NO:1;
- (ii) a peptide comprising the amino acid sequence SEQ ID NO:2;
- (iii) a peptide comprising the amino acid sequence SEQ ID NO:3;
- and (iv) a peptide comprising the amino acid sequence SEQ ID NO:4, wherein the administration comprises:
- (a) administration of a nucleic acid encoding the at least one peptide;
- (b) administration of a peptide carrier system comprising the at least one peptide;
- or
- (c) administration of a CAR-T cell that expresses the at least one peptide.
Dependencies are inferred from the claim text.